125 related articles for article (PubMed ID: 19955841)
1. Phosphorylation status of Fas-associated death domain-containing protein regulates telomerase activity and strongly correlates with prostate cancer outcomes.
Matsumura Y; Shimada K; Tanaka N; Fujimoto K; Hirao Y; Konishi N
Pathobiology; 2009; 76(6):293-302. PubMed ID: 19955841
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression.
Shimada K; Matsuyoshi S; Nakamura M; Ishida E; Konishi N
J Pathol; 2005 Aug; 206(4):423-32. PubMed ID: 15906275
[TBL] [Abstract][Full Text] [Related]
3. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation status of Fas-associated death domain protein is associated with biochemical recurrence after radical prostatectomy.
Ikeda T; Tanaka N; Shimada K; Matsumura Y; Miyake M; Anai S; Tomioka A; Okajima E; Hirayama A; Fujimoto K; Konishi N; Hirao Y
Urology; 2013 Mar; 81(3):607-10. PubMed ID: 23352370
[TBL] [Abstract][Full Text] [Related]
5. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo.
Koga S; Hirohata S; Kondo Y; Komata T; Takakura M; Inoue M; Kyo S; Kondo S
Anticancer Res; 2001; 21(3B):1937-43. PubMed ID: 11497281
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
[TBL] [Abstract][Full Text] [Related]
7. Expression of nuclear and cytoplasmic phosphorylated FADD in gastric cancers.
Yoo NJ; Lee SH; Jeong EG; Lee JW; Soung YH; Nam SW; Kim SH; Lee JY; Lee SH
Pathol Res Pract; 2007; 203(2):73-8. PubMed ID: 17207586
[TBL] [Abstract][Full Text] [Related]
8. Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT.
Iczkowski KA; Huang W; Mazzucchelli R; Pantazis CG; Stevens GR; Montironi R
Cancer; 2004 Jan; 100(2):294-9. PubMed ID: 14716763
[TBL] [Abstract][Full Text] [Related]
9. The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer.
Sun PM; Wei LH; Luo MY; Liu G; Wang JL; Mustea A; Könsgen D; Lichtenegger W; Sehouli J
Eur J Obstet Gynecol Reprod Biol; 2007 Feb; 130(2):249-57. PubMed ID: 16519988
[TBL] [Abstract][Full Text] [Related]
10. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
[TBL] [Abstract][Full Text] [Related]
11. Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells.
Jagadeesh S; Kyo S; Banerjee PP
Cancer Res; 2006 Feb; 66(4):2107-15. PubMed ID: 16489011
[TBL] [Abstract][Full Text] [Related]
12. A novel human cell culture model for the study of familial prostate cancer.
Yasunaga Y; Nakamura K; Ewing CM; Isaacs WB; Hukku B; Rhim JS
Cancer Res; 2001 Aug; 61(16):5969-73. PubMed ID: 11507036
[TBL] [Abstract][Full Text] [Related]
13. Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma.
Gertler R; Rosenberg R; Stricker D; Werner M; Lassmann S; Ulm K; Nekarda H; Siewert JR
Cancer; 2002 Nov; 95(10):2103-11. PubMed ID: 12412163
[TBL] [Abstract][Full Text] [Related]
14. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
[TBL] [Abstract][Full Text] [Related]
15. Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase.
Mai W; Kawakami K; Shakoori A; Kyo S; Miyashita K; Yokoi K; Jin M; Shimasaki T; Motoo Y; Minamoto T
Clin Cancer Res; 2009 Nov; 15(22):6810-9. PubMed ID: 19903789
[TBL] [Abstract][Full Text] [Related]
16. Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment.
Miyata Y; Kanda S; Sakai H; Hakariya T; Kanetake H
Urology; 2005 Jun; 65(6):1238-43. PubMed ID: 15922418
[TBL] [Abstract][Full Text] [Related]
17. Expression of human telomerase reverse transcriptase (hTERT) protein is significantly associated with the progression, recurrence and prognosis of oral squamous cell carcinoma in Taiwan.
Chen HH; Yu CH; Wang JT; Liu BY; Wang YP; Sun A; Tsai TC; Chiang CP
Oral Oncol; 2007 Feb; 43(2):122-9. PubMed ID: 16798059
[TBL] [Abstract][Full Text] [Related]
18. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.
Karam JA; Lotan Y; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF
Prostate; 2007 May; 67(6):614-22. PubMed ID: 17299799
[TBL] [Abstract][Full Text] [Related]
19. A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes.
Gu Y; Kim KH; Ko D; Nakamura K; Yasunaga Y; Moul JW; Srivastava S; Arnstein P; Rhim JS
Int J Oncol; 2004 Oct; 25(4):1057-64. PubMed ID: 15375556
[TBL] [Abstract][Full Text] [Related]
20. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
